About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Pfizer, Vertex Execs Are Victims of Facebook Faker; Forbes, WSJ Also Targeted

By Jim Edwards | Apr 29, 2009

Someone is impersonating prominent members of the pharma and biotech world on Facebook, including Vertex Pharmaceuticals chief executive Joshua Boger, a chief science officer at Pfizer and Forbes drug writer Matt Herper. The latter wrote a half-amusing, half-disturbing story for Forbes about how he was duped by the Facebook faker, friending “Rick Weiss,” the former Washington Post science writer, only to later find out that the real Weiss had not sent him a friend request.

Herper even conversed with “Rick Weiss” about a YouTube video they had both seen, and remained convinced he was friends with the real Weiss until he called the Post writer on the phone to check. The faker had somehow friended the real victims, copied their profiles, and then set themselves up with new Facebook accounts under their victim’s identity — thus the fake profiles looked real.

That’s the amusing part. Here’s where it gets disturbing:

This pretender was one of 100 impersonators of scientists, journalists and science policy wonks uncovered by Lucas Laursen, a reporter at Nature, the scientific journal. Most of the people who were copied are somehow linked to the biotech industry, and many are linked to the especially controversial field of embryonic stem cell research. Ruth McKernan, chief scientific officer of Pfizer’s regenerative medicine unit is on the list; so was University of Wisconsin bioethicist Alta Charo, whose thinking about stem cells has been hugely influential.

Herper wasn’t “Rick Weiss’s” only victim; the faker had also friended a Wall Street Journal reporter, a lawyer and a public relations executive.

Facebook has since killed off “Rick Weiss” but the bio-faker’s other identities remain out there. Facebook declined to comment for Herper’s piece.

Image: A digital representation of the real Herper.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Social media pitfall No. 7: Facebook's pharma fakers

    Fierce Pharma - 207 days 12 hours 4 minutes ago

    null null null null

  • Vertex founder: Adapt or die!

    FierceMarkets - 230 days 10 hours 14 minutes ago

    Joshua Boger has made a prominent reputation for himself as founder and CEO of Vertex . Now he offers some advice for others who want to follow the same biotech path. In a conversation with the Charlotte Business Journal , he offers the following to entrepreneurs: "Follow your own business plan. Don't follow the winds that blow back and...

  • Vertex CEO resigns as telaprevir advances

    FierceMarkets - 290 days 14 hours 23 minutes ago

    After two decades at the helm of Vertex Pharmaceuticals, CEO Dr. Joshua Boger announced that he will retire in May. Shire chairman Matthew Emmens will take over the top spot after Boger's departure and will immediately become president of the company. Vertex is valued at $5 billion but has lost $2 billion over its 20-year history. Its lead...

  • Pharma women rank among world's most powerful

    Fierce Pharma - 95 days 7 hours 33 minutes ago

    Top executives from several leading pharma companies made Forbes' "The World's Most Powerful Women" list. The annual feature ranks women based on visibility in the media and organization or country size. This year's list includes Johnson and Johnson's Sherilyn McCoy at 65th, GlaxoSmithKline's Deirdre Connelly at 73rd, Pfizer's Amy...

  • With Avastin Effectiveness Questioned, Roche's Acquisition of Genentech Looks Hasty

    BNET Pharma - 173 days 7 hours 3 minutes ago

    The news for Roche on Avastin gets worse: Forbes’ Matt Herper just published a lengthy piece which suggests, in layman’s terms, that the $4.8 billion cancer drug kinda doesn’t work very well. Here’s the nut: … on average, Avastin only increases patients’ life spans by a couple months. The big sales are partly a result of the high...

Links from the Web Buzz:
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement